76.35 -1.65 (-2.12%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 108.58 ![]() |
1-year : | 126.83 ![]() |
Resists | First : | 92.97 ![]() |
Second : | 108.58 ![]() |
Pivot price | 70.62 ![]() |
|||
Supports | First : | 71.78 ![]() |
Second : | 58.68 |
MAs | MA(5) : | 72.26 ![]() |
MA(20) : | 72.06 ![]() |
MA(100) : | 70.12 ![]() |
MA(250) : | 41.64 ![]() |
|
MACD | MACD : | -1.5 ![]() |
Signal : | -2.5 ![]() |
%K %D | K(14,3) : | 68.9 ![]() |
D(3) : | 56.4 ![]() |
RSI | RSI(14): 53.9 ![]() |
|||
52-week | High : | 98.87 | Low : | 4.61 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ WGS ] has closed below upper band by 27.4%. Bollinger Bands are 16.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 78.58 - 79 | 79 - 79.35 |
Low: | 73.5 - 73.95 | 73.95 - 74.34 |
Close: | 75.59 - 76.38 | 76.38 - 77.04 |
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
Sun, 16 Feb 2025
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? - Benzinga
Sun, 16 Feb 2025
GeneDx (WGS) Projected to Post Earnings on Tuesday - Defense World
Mon, 10 Feb 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS - Finansavisen
Fri, 07 Feb 2025
GeneDX Holdings Stock Q4 2024 Earnings Preview (NASDAQ:WGS) - Seeking Alpha
Tue, 29 Oct 2024
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights - BioSpace
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Healthcare Information Services
|
|
Shares Out | 27 (M) |
Shares Float | 19 (M) |
Held by Insiders | 17.8 (%) |
Held by Institutions | 74.4 (%) |
Shares Short | 2,140 (K) |
Shares Short P.Month | 2,150 (K) |
EPS | -3.09 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 7.44 |
Profit Margin | -31.3 % |
Operating Margin | -10.2 % |
Return on Assets (ttm) | -8.3 % |
Return on Equity (ttm) | -36.5 % |
Qtrly Rev. Growth | 44.2 % |
Gross Profit (p.s.) | 5.92 |
Sales Per Share | 9.72 |
EBITDA (p.s.) | -1.42 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -55 (M) |
Levered Free Cash Flow | -20 (M) |
PE Ratio | -24.71 |
PEG Ratio | 0 |
Price to Book value | 10.24 |
Price to Sales | 7.84 |
Price to Cash Flow | -38.02 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |